<DOC>
	<DOCNO>NCT00147550</DOCNO>
	<brief_summary>MEK critical member MAPK pathway involve growth survival cancer cell . PD-325901 new drug design block pathway kill cancer cell . The purpose study study effectiveness PD-325901 patient colon cancer , breast cancer , melanoma . PD-325901 give mouth pill twice day , CT scan do biopsy take tumor treatment measure effect drug . Blood sample take measure amount drug blood .</brief_summary>
	<brief_title>MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer , Colon Cancer , And Melanoma .</brief_title>
	<detailed_description>The study prematurely discontinue March 15 , 2007 due safety concern , specifically ocular neurological toxicity present 10 mg twice-a-day high dos .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<criteria>Age &gt; = 18 year old Tumor accessible biopsy willingness undergo baseline 1 post treatment biopsy Biopsiable , histologically cytologically confirm metastatic inoperable breast cancer , colon cancer , melanoma . Prior treatment requirement : ) 2 prior cytotoxic chemotherapy regimens metastatic disease patient breast colon cancer ; ii ) No prio cytotoxic therapy patient melanoma , iii ) measurable lesion ( ) irradiate . Adequate renal , liver , bone marrow function , determine within 2 week prior first treatment , define follow : Serum creatinine &lt; 1.5 x ULN , total bilirubin &lt; 2 x ULN , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 3 x ULN ( &lt; 5 x ULN patient liver involvement ) ; absolute neutrophil count ( ANC ) &gt; 1500/ul ; platelet &gt; 100,000/ul Hemoglobin &gt; 9.0 g/dL . Treatment transfusion erythropoietin elevate hemoglobin level eligibility purpose permit . Patients must discontinue erythropoietin least 2 week prior first dose study medication Serum calcium &lt; 1 x ULN phosphorus &lt; 1 x ULN Patients reproductive potential must use adequate method birth control . Patients may pregnant breastfeeding . ECOG Status 0,1 , 2 . Must able swallow intact study medication gastrointestinal disorder may affect absorption drug Must able follow instruction protocol specify procedure , daily care giver responsible administer study medication . Must able give write informed consent . No parathyroid disorder history malignancy associate hypercalcemia No ongoing radiation therapy radiocytotoxic therapy within prior 4 week ; No immunotherapy , biologic therapy , hormonal , molecular target therapy within prior 2 week No concurrent serious infection lifethreatening illness ( unrelated tumor ) No history cancer present condition ( except nonmelanoma skin cancer carcinoma situ cervix ) , unless complete remission therapy disease minimum 3 year No untreated brain metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>